Justin Zelin

Mr. Justin Zelin is a Director at BTIG LLC.
His research coverage focuses on the biotechnology sector, where he specializes in cell therapy, targeted oncology, immunology and auto-immune disease therapeutics.
Prior to BTIG, Mr. Zelin was a Biotech Equity Research Analyst at B. Riley Securities.
Previously, he held biotech equity research associate roles at Canaccord Genuity and SVB Leerink.
Earlier in his career, Mr. Zelin worked in both academic and industry labs including Agenus, Harvard University and Brigham and Women’s Hospital.
He was also a member of Harvard University’s teaching staff for more than five years.
He earned a master’s degree in biotechnology and a bachelor’s degree in biology from Harvard University.